We continue to see a ramping up the clinical validation testing of rapamycin in humans for anti-aging applications. (slide source above from Matt Kaeberlein).
The PEARL clinical study on rapamycin is ongoing with a few hundred participants.
This week Adam announced a new study he is PI on, to test whether a rapamycin analog (rapalog) can improve physiological and molecular hallmarks of aging in humans.
This adds to 3 other recently-funded human clinical trials for rapamycin in different applications:
Jonathan An at the University of Washington got funding for his study on rapamycin for prevention of periodontal disease.
A clinical trial is underway at Columbia University to determine whether rapamycin can reverse premature ovarian failure (improve fertility) in women - as early research has suggested.
Dr. Brad Stanfield (in New Zealand) is working on funding for a study focused on testing rapamycin to delay muscle aging in the elderly.
Dudley Lamming tweeted:
It’s beyond time to rigorously test the hypothesis that#mTOR inhibition can safely promote healthy aging in humans. With@maml_UWMadison and many other clinical & translational researchers@uw_medicine, over the next three years we will find out!
Matt Kaeberlein commented on twitter:
Congratulations to@lamminglab@maml_UWMadison and colleagues. Agree - beyond time. Exciting to see multiple clinical trials starting this year to assess the impact of rapamycin on different age-related endpoints. Guess I need to update my slide before tomorrow…